The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Insights into premedication and infusion-related reactions with subcutaneous isatuximab in myeloma
Fredrik Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the potential to de-escalate premedication use with subcutaneous isatuximab, suggesting that it may not be necessary after the first few cycles, particularly with subcutaneous treatment. Dr Schjesvold highlights that a pooled analysis of isatuximab subcutaneous studies showed no increase in infusion-related reactions when premedication was stopped after four cycles, making it a safe and feasible approach. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
